1. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). (October 2018) Authors: van Rossum, A.G.J.; Kok, M.; van Werkhoven, E.; Opdam, M.; Mandjes, I.A.M.; van Leeuwen – Stok, A.E.; van Tinteren, H.; Imholz, A.L.T.; Portielje, J.E.A.; Bos, M.M.E.M.; van Bochove, A.; Wesseling, J.; Rutgers, E.J.; Linn, S.C.; Oosterkamp, H.M. Journal: European journal of cancer Issue: Volume 102(2018) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients. (November 2022) Authors: Wang, Y.; Dackus, G.M.; Broeks, A.; Giardiello, D.; Hauptmann, M.; Jóźwiak, K.; Koop, E.A.; Opdam, M.; Siesling, S.; Sonke, G.S.; Stathonikos, N.; ter Hoeve, N.D.; van der Wall, E.; van Duerzen, C.H.; van Diest, P.J.; Voogd, A.C.; Vreuls, W.; Linn, S.C.; Schmidt, M.K. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0412 EFFECT OF METFORMIN ON CLINICAL GOUT OUTCOMES IN GOUT PATIENTS WITH DIABETES MELLITUS. (2nd June 2020) Authors: Veenstra, F.; Verhoef, L. M.; Opdam, M.; Den Broeder, A.; Kwok, W. Y.; Meek, I.; Van den Hoogen, F.; Flendrie, M.; Van Herwaarden, N. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗